Comparative Study on Efficacy of Anti-Seizure Medication Therapies for Epilepsy Patients

Strategic Insights -

Research conducted by a team of neurologists at Sichuan University has shed light on the most effective treatment combinations for patients with epilepsy who have failed to respond to sodium valproate monotherapy. The study aimed to compare the therapeutic efficacy of five anti-seizure medication combinations: valproate plus lamotrigine, levetiracetam, oxcarbazepine, topiramate, or carbamazepine. The results indicate that combining valproate with lamotrigine demonstrates significantly higher efficacy for subjects with generalized epilepsy, while combining valproate with oxcarbazepine may be more effective for subjects with focal epilepsy.

Key Takeaways:

  • The study involved 2656 patients with epilepsy who had failed to respond to sodium valproate monotherapy.
  • The five anti-seizure medication combinations studied were:

+ Valproate plus lamotrigine (VPA + LTG)

+ Valproate plus levetiracetam (VPA + LEV)

+ Valproate plus oxcarbazepine (VPA + OXC)

+ Valproate plus topiramate (VPA + TPM)

+ Valproate plus carbamazepine (VPA + CBZ)

  • The 50% response rates for subjects with generalized epilepsy were:

+ 89.6% for VPA + LTG

+ 81.0% for VPA + OXC

+ 77.9% for VPA + LEV

+ 77.7% for VPA + TPM

+ 75.9% for VPA + CBZ

  • The lamotrigine group demonstrated significantly higher efficacy than the levetiracetam, topiramate, and carbamazepine groups (P = 0.01).

Statistics:

  • 2656 patients with epilepsy were included in the study.
  • 50% response rates for subjects with generalized epilepsy were:

+ 89.6% for VPA + LTG

+ 81.0% for VPA + OXC

+ 77.9% for VPA + LEV

+ 77.7% for VPA + TPM

+ 75.9% for VPA + CBZ

Sources:

  • A comparative study on the efficacy of different combinational anti-seizure medication therapies following valproate monotherapy failure. Acta Epileptologica, 2025;7(1):48.
  • Researchers from Sichuan University Describe Findings in Epilepsy (A comparative study on the efficacy of different combinational anti-seizure medication therapies following valproate monotherapy failure). Health & Medicine Week. October 31, 2025; p 6727.